Last reviewed · How we verify
FEC-T+Pertuzumab
FEC-T+Pertuzumab combines chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide, and docetaxel) with pertuzumab, a HER2-targeted monoclonal antibody that blocks HER2 dimerization to prevent tumor cell growth.
FEC-T+Pertuzumab combines chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide, and docetaxel) with pertuzumab, a HER2-targeted monoclonal antibody that blocks HER2 dimerization to prevent tumor cell growth. Used for HER2-positive early-stage breast cancer (neoadjuvant setting).
At a glance
| Generic name | FEC-T+Pertuzumab |
|---|---|
| Also known as | Fluorouracil; 500 mg/m2; day 1, Epirubicine; 90 mg/m2; day 1, Cyclophosphamide 500 mg/m2; day 1, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg), Pertuzumab; 420 mg (loading dose 840 mg); day 1 |
| Sponsor | The Netherlands Cancer Institute |
| Drug class | Chemotherapy regimen + HER2 dimerization inhibitor |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FEC-T is a standard neoadjuvant chemotherapy regimen for breast cancer. Pertuzumab is a HER2 dimerization inhibitor that prevents HER2 from pairing with other HER family receptors, blocking downstream signaling. The combination targets HER2-positive breast cancer through both cytotoxic chemotherapy and targeted HER2 pathway inhibition.
Approved indications
- HER2-positive early-stage breast cancer (neoadjuvant setting)
Common side effects
- Neutropenia
- Anemia
- Nausea/vomiting
- Alopecia
- Diarrhea
- Cardiac dysfunction
Key clinical trials
- Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (PHASE3)
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (PHASE4)
- A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |